Sat, Dec 27, 2014, 8:19 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

healthrx74 18 posts  |  Last Activity: Nov 25, 2014 4:28 PM Member since: Aug 9, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Sell Off into the Close

    by craigokess Nov 25, 2014 4:08 PM
    healthrx74 healthrx74 Nov 25, 2014 4:28 PM Flag

    hahahahahahaha up 15.83 % for the day is a sell off? hahahhahahhahahhahahaha..thanks I neded that

  • healthrx74 healthrx74 Oct 28, 2014 1:34 PM Flag

    Bashers are like Remora fish...just add hands and a beer belly. "Remoras are short, thick sucker fish with fin rays, have no swim bladders and thus have to attach themselves to animals such as large sharks and sea turtles by using a sucking disc on the top of their heads. They are not harmful parasites, but are just simply along for the ride."

  • healthrx74 healthrx74 Oct 28, 2014 12:00 PM Flag

    Bourbon....well said. This is simple to understand and worth repeating daily for new investors with Patcarr832's observation of.....#(4) 100% efficacy in animal studies

  • healthrx74 healthrx74 Oct 28, 2014 11:44 AM Flag

    paid by the post and morally challenged...(to say these guys are mentally challenged would be an insult to the mentally challenged)

  • healthrx74 healthrx74 Oct 28, 2014 7:29 AM Flag

    People in the News - Philadelphia Inquirer
    Jennifer Laux was hired as vice president, commercial, at Inovio Pharmaceuticals Inc., a Plymouth Meeting developer of oncology and infectious disease DNA immunotherapies. She had been vice president, cardiovascular marketing, at Boehringer Ingelheim.

  • healthrx74 healthrx74 Oct 21, 2014 9:54 PM Flag

    Short People got no reason
    Short People got no reason
    Short People got no reason
    To live

    They got little hands
    Little eyes
    They walk around
    Tellin' great big lies
    They got little noses
    And tiny little teeth
    They wear platform shoes
    On their nasty little feet

    Well, I don't want no Short People
    Don't want no Short People
    Don't want no Short People
    `Round here

  • healthrx74 healthrx74 Oct 21, 2014 9:11 PM Flag

    Thanks's more coverage on the announcement that's easy to read

    Inovio, Penn and MedImmune get $12.2M to take on the flu

    Philadelphia Business Journal

    Researchers from Inovio Pharmaceuticals and MedImmune, along with scientists from the Perelman School of Medicine at the University of Pennsylvania, received $12.2 million from the Department of Defense to develop new treatments for influenza and antibiotic-resistant bacteria.

    The grant was awarded by the Defense Advanced Research Projects Agency, an agency of the defense department that creates and supports novel technologies for national security.

    The companies and university researchers plan to use the funds to develop and assess DNA-based monoclonal antibodies for infectious disease treatment. Monoclonal antibodies produced by a single clone of cells or a cell line.

    The project will focus on new technology, initially developed at Penn in the lab of David Weiner, a professor of pathology and laboratory medicine, to provide a way to rapidly protect people against emerging infections by developing novel synthetic antibodies produced by the patients themselves.

    Inovio (NASDAQ: INO) of Plymouth Meeting, Pa., has licensed DNA-based monoclonal antibodies developed at Penn as part of its effort to develop universal vaccines.

    "Monoclonal antibody technology has already achieved multiple market-proven product successes," said Dr. J. Joseph Kim, president and CEO of Inovio, "and we believe DNA-based monoclonal antibody technology could significantly extend the medical benefits and efficiency of this concept."

    MedImmune of Gaithersburg, Md., is a subsidiary of AstraZeneca (NYSE: AZN),

  • Inovio is presenting at these upcoming scientific, partnering, or investor conferences:


    Stifel Healthcare Conference
    November 18-19, 2014

    Brean Capital Life Science Conference
    November 24, 2014

    Piper Jaffray Healthcare Conference
    December 2-3, 2014


    World Vaccine Congress 2014
    October 13-15, 2014 - JUST HAPPENED

    Cell & Gene Therapy
    October 28, 2014

    Oh yeah, it also has a current $21 Price Target


  • healthrx74 healthrx74 Oct 19, 2014 11:16 PM Flag

    Recent Insider Buying in addition to Dr. Kim

    10/09/2014 Peter D. Kies
    CFO 3,960 Acquisition at $10.1 per share. 39,996

    08/22/2014 Mort C. Collins
    Director 4,000 Acquisition at $10.01 per share. 40,040
    08/22/2014 Mort C. Collins
    Director 4,000 Acquisition at $10.01 per share. 40,040
    08/21/2014 Mort C. Collins
    Director 14,000 Acquisition at $9.75 per share. 136,500
    08/21/2014 Mort C. Collins
    Director 14,000 Acquisition at $9.75 per share. 136,500

  • Since the 15th World Vaccine Congress in Brussels just occurred last week, I thought the following from the September interview with Dr. Sardesai might shed light on what just happened there.

    What are the major investment areas at the moment in your company and how is this expected to progress in the future?
    Inovio is focused on developing vaccines and immunotherapies targeting oncology and infectious diseases. Our clinical pipeline includes immunotherapies targeting HPV associated cancers and pre-cancers (cervical, head and neck, VIN, VAIN, AIN) as well as immunotherapies targeting HBV, HCV, HIV, and prostate, breast, lung, and pancreatic cancers. These represent significant investment areas for the company. Additionally, with the successful results from the Phase II study, preparing for and initiating the Phase III study represents an important major investment for the company.

    What would you like to gain from our congress?
    WVC represents an exciting forum to share vaccine and immunology driven product development results and meet our peers in industry, academia, and government/regulatory agencies. It’s an opportunity to meet potential partners as well as learn from the experiences of our peers.

  • Reply to

    The Week in Review - 10/17/14

    by coop99man Oct 17, 2014 4:25 PM
    healthrx74 healthrx74 Oct 18, 2014 11:50 AM Flag

    Great as always. Thanks for all the effort you put into "The Week in Review."

  • Reply to

    NBC10 Philadelphia- News Video

    by healthrx74 Oct 17, 2014 9:41 PM
    healthrx74 healthrx74 Oct 18, 2014 11:47 AM Flag

    That's great dm and stillinshock!....Thanks to everyone for all of the great responses and continuing efforts to get the message out to others about what this company is doing and can offer.

  • Reply to

    NBC10 Philadelphia- News Video

    by healthrx74 Oct 17, 2014 9:41 PM
    healthrx74 healthrx74 Oct 17, 2014 11:19 PM Flag

    Thanks Kenneth! ...Good night all...

  • Reply to

    NBC10 Philadelphia- News Video

    by healthrx74 Oct 17, 2014 9:41 PM
    healthrx74 healthrx74 Oct 17, 2014 10:05 PM Flag

    Thanks, I posted a link also and it was removed.....if this happens again anyone can just go to NBC philadelphia's main news page...its with the EBOLA news near the bottom

  • Local Company Developing Ebola Vaccine

    Inovio Pharmaceuticals in Montgomery County is developing a synthetic Ebola vaccine that will be tested on humans after tests on animals proved positive.

    Nice video with interview with Dr. Kim

  • Reply to

    EBOLA Classified by CDC as "A" Type Virus

    by sacbunt306 Oct 3, 2014 9:12 PM
    healthrx74 healthrx74 Oct 3, 2014 11:49 PM Flag

    Good video Sac ..thanks ...for those who haven't seen it yet
    Charles Duncan, Managing Director and Senior Research Analyst, Piper Jaffray shares how Inovio is responding to the Ebola outbreak (also discusses how platform is effective in other areas)

  • And it wasn't because of Ebola....

    Fight Against Cancer Campaign

    In an interview with Inovio’s CEO Dr. J. Joseph Kim, he discussed the ability of DNA-based immune therapies to activate targeted T cell responses to kill cancer cells and why immunotherapies are positioned to become a powerful weapon in the war against cancer.
    September 2014

    Health: Local Researchers Developing MERS Virus Vaccine

    In a TV interview, Dr. Joseph Kim and Dr. David Weiner discuss the MERS virus and Inovio’s effort to create a potential DNA vaccine to combat this infectious disease.

    Inovio Pharma's drug to treat cervical lesions meets trial goal
    Wed Jul 23, 2014 10:30am EDT

    (Reuters) - Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial.

    HIV Prevention Makes Strides

    Dr. Joseph Kim discusses Inovio's approach to prevent and treat HIV infection.

    October 2013

    Delivering a Cure for Hepatitis C Infection

    Dr. Joseph Kim discusses Inovio's therapeutic HCV vaccine

    June 2013

    Inovio Says H7N9 Bird Flu Vaccine Effective in Mice

    Inovio's vaccine has shown promising results in preclinical studies against the virulent H7N9 avian influenza strain

  • healthrx74 healthrx74 Sep 28, 2014 7:10 PM Flag

    This is a good start and hopefully will gain some traction. AF was singled out, by name, by a Pulitzer Prize winning lets see what happens next.

    Washington Post
    Steven Pearlstein is a business and economics columnist who writes about local, national and international topics. He joined the Post in 1988 as deputy business editor, and has been defense industry reporter, economic correspondent and Canadian correspondent. He is also moderator of the Post’s On Leadership site. In the fall of 2011, he will become the Robinson Professor of Political and International Affairs at George Mason University. Pearlstein was awarded the Pulitzer Prize for commentary in 2008 for columns anticipating and explaining the global financial crisis.

1.07+0.04(+3.88%)Dec 26 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST